Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение гастрита, дуоденита

Литература / References

  1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5. DOI: 10.1016/ s0140-6736(84)91816-6
  2. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. ClinMicrobiolRev. 2006;19(3):449–90. DOI: 10.1128/CMR.00054-05
  3. Graham D.Y., Opekun A.R., Osato M.S., El-Zimaity H.M., Lee C.K., Yamaokaet Y., et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004;53(9):1235–43. DOI: 10.1136/gut.2003.037499
  4. Ansari S., Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019;11(11):677. DOI: 10.3390/ toxins11110677
  5. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402. DOI: 10.1038/35006081
  6. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infectionthe Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. DOI: 10.1136/gutjnl-2016-312288
  7. Sugano K., Tack J., Kuipers E.J., Graham D.Y., ElOmar E.M., Miura S., et al. Kyoto global consensus report on Helicobacter pylorigastritis. Gut. 2015;64:1353– 67. DOI: 10.1136/gutjnl-2015-309252
  8. Ивашкин В.Т., Маев И.В., Каприн А.Д., Агапов М.Ю., Андреев Д.Н., Водолеев А.С. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Рос журн гастроэнтерол гепатол колопроктол. 2019;29(5):53–74. [Ivashkin V.T., Mayev I.V., Kaprin A.D., Agapov M.Yu., Andreev D.N., Vodoleev A.S., et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Rus J Gastroenterol Hepatol Coloproctol. 2019;29(5):53–74 (In Russ.)]. DOI: 10.22416/1382-4376-2019-29-5-53-74
  9. Симаненков В.И., Маев И.В., Ткачева О.Н, Алексеенко С.А., Андреев Д.Н., Бордин Д.С. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. [Simanenkov V.I., Maev I.V., Tkacheva O.N., Alekseenko S.A., Andreev D.N., Bordin D.S., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (In Russ.)]. DOI: 10.15829/1728-8800-2021-2758
  10. Hall S.N., Appelman H.D. Autoimmune Gastritis. Arch Pathol Lab Med. 2019;143(11):1327–31. DOI: 10.5858/ arpa.2019-0345-RA
  11. Rodriguez-Castro K.I., Franceschi M., Miraglia C., Russo M., Nouvenne A., Leandro G., et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed. 2018;89(8-S):100–3. DOI: 10.23750/abm.v89i8-S.7919
  12. Лосик Е.А., Селиванова Л.С., Антонова Т.В., Лапина Т.Л., Тертычный А.С., Ивашкин В.Т. Морфологические критерии диагноза аутоиммунного гастрита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(5):13–20. [Losik Y.A., Selivanova L.S., Antonova T.V., Lapina T.L., Tertychny A.S., Ivashkin V.T. Morphological diagnostic criteria of autoimmune gastritis. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(5):13–20 (In Russ.)]. DOI: 10.22416/13824376-2016-26-5-13-20
  13. Герман С.В., Зыкова И.Е., Модестова А.В., Ермаков Н.В. Распространенность инфекции H. pylori среди населения Москвы. Рос журн гастроэнтерол гепатол колопроктол. 2010;20(2):25–30. [German S.V., Zykova I.Ye., Modestova A.V., Yermakov N.V. Prevalence of H. pylori infection in the Moscow population. Rus J Gastroenterol Hepatol Coloproctol. 2010;20(2):25–30 (In Russ.)].
  14. Рахманин Ю.А., Зыкова И.Е., Федичкина Т.П., Соленова Л.Г., Герман С.В., Модестова А.В., Кислицин В.А. Изучение территориального раcпределения инфицированности Helicobacter pylori трудоспособного населения г. Москвы в ходе диспансеризации производственных контингентов. Гигиена и санитария. 2013;92(5):79–82. [Rakhmanin Yu.A., Zykova I.Ye., Fedichkina T.P., Solenova L.G., German S.V., Modestova A.V., Kislitsin V.A. Regional distribution of Helicobacter pylori infection of able-bodied population of Moscow at medical examination of the production staff. Gigiyena i sanitariya 2013; 92(5):79–82 (In Russ.)].
  15. Сварваль А.В., Ферман Р.С., Жебрун А.Б. Изучение динамики превалентности инфекции, обусловленной Helicobacter pylori, среди различных возрастных групп населения Санкт-Петербурга в 2007–2011 годах. Инфекция и иммунитет. 2012;2(4):741–6. [Svarval A.V., Ferman R.S., Zhebrun A.B. Helicobacter pylori prevalence dynamics in different age cohorts of St. Petersburg population in 2007–2011. Infection and Immunity. 2012. 2(4):741-6 (In Russ.)].
  16. Решетников О.В., Курилович С.А., Кротов С.А., Кротова В.А. Хеликобактерная инфекция в сибирских популяциях. Бюл. СОРАМН. 2010;30(2):88–93. [Reshetnikov O.V., Kurilovich S.A., Krotov S.A., Krotova V.A. Helicobacter infection in populations of Siberia. Bull. SB RAMS. 2010; 30(2):88-93 (In Russ.)].
  17. Цуканов В.В., Третьякова О.В., Амельчугова О.С., Каспаров Э.В., Родина Д. В., Васютин А.В. и др. Распространенность атрофического гастрита тела желудка у населения г. Красноярска старше 45 лет. Рос журн гастроэнтерол гепатол колопроктол 2012;22(4):27–31. [Tsukanov V.V., Tretyakova O.V., Amelchugova O.S., Kasparov E.V., Rodina D.V., Vasyutin A.V. et al. Prevalence of atrophic corpus gastritis at Krasnoyarsk over 45 year-old population. Rus J Gastroenterol Hepatol Coloproctol. 2012;22(4):27–31 (In Russ.)].
  18. Штыгашева О.В., Цуканов В.В. Распространенность инфекции Helicobacter pylori и частота диспептических жалоб у населения Хакасии. Рос журн гастроэнтерол гепатол колопроктол. 2004;14(1):33–6. [Shtygasheva O.V., Tsukanov V.V. Prevalence of Helicobacter pylori infection and frequency of dispeptic symptoms in Khakasia population. Rus J Gastroenterol Hepatol Coloproctol. 2004;14(1):33–6 (In Russ.)].
  19. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996;20(10):1161–81. DOI: 10.1097/00000478- 199610000-00001
  20. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. H. pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9. DOI: 10.1056/NEJMoa001999
  21. Meining A., Bayerdörffer E., Müller P., et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998;432(4):311–14. DOI: 10.1007/s004280050171
  22. Miehlke S., Hackelsberger A., Meining A., Hatz R., Lehn N., Malfertheiner P., et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer. 1998;78(2):263–6. DOI: 10.1038/bjc.1998.475
  23. Rugge M., Meggio A., Pennelli G., Piscioli F., Giacomelli L., De Pretis G., et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56(5):631– 6. DOI: 10.1136/gut.2006.106666
  24. Аруин Л.И., Кононов А.В., Мозговой С.И. Международная классификация хронического гастрита: что следует принять и что вызывает сомнения. Архив патологии. 2009;71(4):11–8. [Aruin L.I., Kononov A.V., Mozgovoy S.I. International classification of chronic gastritis: what to accept or revisit. Pathology Archive. 2009; 71(4):11-18. (In Russ.].
  25. Кононов А.В., Потрохова Е.А., Мозговой С.И., Поморгайло Е.Г., Новиков Д.Г. Новая медицинская технология «Молекулярно-генетическая методика прогноза и патоморфологический мониторинг риска развития рака желудка кишечного типа при Helicobacter pyloriинфекции», разрешение Федеральной службы в сфере здравоохранения и социального развития № 2010/220 от 10 июня 2010 г., серия АА 0000001. [Kononov A.V., Potrokhova E.A., Mozgovoy S.I., Pomorgaylo E.G., Novikov D.G. New medical technique “Molecular genetic prognosis and pathomorphological risk monitoring (In Russ.)].
  26. Capelle L.G., de Vries A.C., Haringsma J., Borg F.T., de Vries R.A., Bruno M., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. GastrointestEndosc. 2010;71(7):1150–8. DOI: 10.1016/j.gie.2009.12.029
  27. Kimura K., Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(3):87–97. DOI: 10.1055/s-0028- 1098086
  28. Miwata T., Quach D.T., Hiyama T., Aoki R., Le H.M., Tran P.L., et al. Interobserver and intraobserver agreement for gastric mucosa atrophy. BMC Gastroenterol. 2015;15:95. DOI: 10.1186/s12876-015-0327-x
  29. Song J.H., Kim S.G., Jin E.H., Lim J.H., Yang S.Y. Risk Factors for Gastric Tumorigenesis in Underlying Gastric Mucosal Atrophy. Gut Liver. 2017;11(5):612–9. DOI: 10.5009/gnl16488
  30. Pimentel-Nunes P., Libânio D., Lage J., Abrantes D., Coimbra M., Esposito G., et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy. 2016;48(8):723–30. DOI: 10.1055/s-0042108435
  31. Кононов А.В., Мозговой С.И., Шиманская А.Г. Прижизненная патолого-анатомическая диагностика болезней органов пищеварительной системы. Клинические рекомендации Российского общества патологоанатомов. М.: Практическая медицина, 2019; 192 . [Kononov A.V., Mozgovoy S.I., Shimanskaya A.G. Life-time morbid anatomy diagnosis of digestive diseases. Clinical recommendations of Russian Society of Pathologists. Moscow: Practical Medicine, 2019; 192 (In Russ.)].
  32. Ивашкин В.Т., Маев И.В., Шептулин А.А., Лапина Т.Л., Трухманов А.С., Картавенко И.М., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Рос журн гастроэнтерол гепатол колопроктол. 2017;27(1):50–61. [Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(1):50–61 (In Russ.)]. DOI: 10.22416/1382-4376-2017-27-1-50-61
  33. Ивашкин В.Т., Маев И.В., Царьков П.В., Королев М.П., Андреев Д.Н., Баранская Е.К. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Рос журн гастроэнтерол гепатол колопроктол. 2020;30(1):49–70. [Ivashkin V.T., Maev I.V., Tsar’kov P.V., Korolev M.P., Andreev D.N., Baranskaya E.K., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Rus J Gastroenterol Hepatol Coloproctol. 2020;30(1):49–70 (In Russ.)]. DOI: 10.22416/1382-4376-2020-30-1-49-70
  34. Carabotti M., Lahner E., Esposito G., Sacchi M.C., Severi C., Annibale B. Upper gastrointestinal symptoms in autoimmune gastritis: A cross-sectional study. Medicine (Baltimore). 2017; 96(1):e5784. DOI: 10.1097/ MD.0000000000005784
  35. Miceli E., Lenti M.V., Padula D., Luinetti O., Vattiato C., Monti C.M., et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):812–4. DOI: 10.1016/j. cgh.2012.02.018
  36. Tenca A., Massironi S., Pugliese D., Consonni D., Mauro A., Cavalcoli F., et al. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. NeurogastroenterolMotil. 2016;28(2):274–80. DOI: 10.1111/nmo.12723
  37. Pruthi H.S., Sharma S.K., Singh B., Anand A.C. Aetiology of upper gastrointestinal haemorrhagean endoscopic study. Med J Armed Forces India. 2000;56(3):188–91. DOI: 10.1016/S0377-1237(17)30162-4
  38. Biecker E. Diagnosis and therapy of non-variceal upper gastrointestinal bleeding. World J Gastrointest Pharmacol Ther. 2015;6(4):172–82. DOI: 10.4292/wjgpt.v6.i4.172
  39. Лосик Е.А., Ивашкин В.Т. Гематологические проявления аутоиммунного гастрита. Рос журн гастроэнтерол гепатол колопроктол. 2016;26(1):37–43. [Losik Ye.A., Ivashkin V.T. Hematological manifestations of autoimmune gastritis. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(1):37–43 (In Russ.)]. DOI: 10.22416/1382-43762016-26-1-37-43
  40. Rusak E., Chobot A., Krzywicka A., Wenzlau J. Anti-parietal cell antibodies — diagnostic significance. Adv Med Sci. 2016;61(2):175–9. DOI: 10.1016/j.advms.2015.12.004
  41. Lahner E., Norman G.L., Severi C., Encabo S., Shums Z., Vannella L., et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–9. DOI: 10.1038/ajg.2009.231
  42. Huang Y.K., Yu J.C., Kang W.M., Ma Z.-Q., Ye X., Tian S.-B., et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One. 2015;10(11):e0142080. DOI: 10.1371/journal. pone.0142080
  43. Zagari R.M., Rabitti S., Greenwood D.C., Eusebi L.H., Vestito A., Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum as- says for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657–67. DOI: 10.1111/ apt.14248
  44. Watabe H., Mitsushima T., Yamaji Y., Okamoto M., Wada R., Kokubo T., et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54(6):764–8. DOI: 10.1136/gut.2004.055400
  45. Kurilovich S., Belkovets A., Reshetnikov O., Openko T., Malyutina S., Ragino Y., et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016;36(1):247–53. PMID: 26722050
  46. Pimentel-Nunes P., Libânio D., Marcos-Pinto R., Areia M., Leja M., Esposito G., et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–88. DOI: 10.1055/a-0859-1883
  47. Banks M., Graham D., Jansen M., Gotoda T., Coda S., di Pietro M., et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545–75. DOI: 10.1136/gutjnl-2018-318126
  48. Zhao Z., Yin Z., Wang S., Wang J., Bai B., Qiu Z., et al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol. 2016;31(9):1539–45. DOI: 10.1111/jgh.13313
  49. Ang T.L., Pittayanon R., Lau J.Y., Rerknimitr R., Ho S.H., Singh R., et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol. 2015;27(12):1473–8. DOI: 10.1097/MEG.0000000000000478
  50. Kikuste I., Marques-Pereira R., Monteiro-Soares M., Pimentel-Nunes P., Areia M., Leja M., et al. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. Scand J Gastroenterol. 2013;48(10):1108–17. DOI: 10.3109/00365521.2013.825315
  51. Pimentel-Nunes P., Dinis-Ribeiro M., Soares J.B., Marcos-Pinto R., Santos C., Rolandaet C., et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endoscopy. 2012;44(3):236–46. DOI: 10.1055/s0031-1291537
  52. East J.E., Vleugels J.L., Roelandt P., Bhandari P., Bisschops R., Dekker E., et al. Advanced endoscopic imaging: European Society of Gastrointestinal Endoscopy (ESGE) Technology Review. Endoscopy. 2016;48(11):1029–45. DOI: 10.1055/s-0042-118087
  53. Rugge M., Genta R.M., Fassan M., Valentini E., Coati I., Guzzinati S., et al. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. Am J Gastroenterol. 2018;113(11):1621–8. DOI: 10.1038/s41395-018-0353-8
  54. Mao X.Y., Xu S.F., Liu Q., Jiang J.X., Zhang H.H., Sang H.M., et al. Anatomical predilection of intestinal metaplasia based on 78,335 endoscopic cases. Saudi J Gastroenterol. 2016;22(2):154–60. DOI: 10.4103/1319- 3767.178528
  55. Kim Y.I., Kook M.C., Cho S.J., Lee J.Y., Kim C.G., Joo J., et al. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages. Helicobacter. 2017;22(6). DOI: 10.1111/hel.12442
  56. Isajevs S., Liepniece-Karele I., Janciauskas D., Moisejevs G., Funka K., Kikuste I., et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol. 2014;26(5):510–3. DOI: 10.1097/MEG.0000000000000082
  57. Varbanova M., Wex T., Jechorek D., Röhl F.W., Langner C., Selgradet M., et al. Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. J Clin Pathol. 2016;69(1):19–25. DOI: 10.1136/jclinpath-2015-202858
  58. Lan H.C., Chen T.S., Li A.F., Chang F.Y., Lin H.C. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol. 2012;12:182. DOI: 10.1186/1471-230X-12-182
  59. Shin C.M., Kim N., Lee H.S., Lee H.E., Lee S.H., Park Y.S., et al. Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/ or intestinal metaplasia. Helicobacter. 2009;14(6):512–9. DOI: 10.1111/j.1523-5378.2009.00726.x
  60. Best L.M., Takwoingi Y., Siddique S., Selladurai A., Gandhi A., Low B., et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3):CD012080. DOI: 10.1002/14651858. CD012080.pub2
  61. Abd Rahim M.A., Johani F.H., Shah S.A., Hassan M.R., Abdul Manaf M.R. 13C-Urea Breath Test Accuracy for Helicobacter pylori Infection in the Asian Population: A Meta-Analysis. Ann Glob Health. 2019;85(1):110. DOI: 10.5334/aogh.2570
  62. Mansori K., Dehghanbanadaki H., Naderpour S., Rashti R., Moghaddam A.B., Moradi Y. A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes. Diabetes Metab Syndr. 2020;14(4):601–7. DOI: 10.1016/j.dsx.2020.05.009
  63. Dechant F.X., Dechant R., Kandulski A., Selgrad M., Weber F., Reischl U., et al. Accuracy of Different Rapid Urease Tests in Comparison with Histopathology in Patients with Endoscopic Signs of Gastritis. Digestion. 2020;101(2):184–90. DOI: 10.1159/000497810
  64. Yakoob J., Jafri W., Abid S., Jafri N., Abbas Z., Hamid S., et al. Role of rapid urease test and histopathology in the diagnosis of Helicobacter pylori infection in a developing country. BMC Gastroenterol. 2005;5:38. DOI: 10.1186/1471-230X-5-38
  65. Hsu W.H., Wang S.S., Kuo C.H., Chen C.Y., Chang C.W., Hu H.M., et al. Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. World J Gastroenterol. 2010;16(23):2926–30. DOI: 10.3748/wjg.v16.i23.2926
  66. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К. и лр. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол. 2018;28(1):55–70. [Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya Y.K., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(1):55–
  67. (In Russ.)]. DOI: 10.22416/1382-4376-2018-28-1-55-70
  68. Ливзан М.А., Кононов А.В., Мозговой С.И. Течение хронического гастрита, ассоциированного с Helicobacter pylori, в постэрадикационном периоде. Экспериментальная и клиническая фармакология. 2007;5:116–23. [Livzan M.A., Kononov A.V., Mozgovoy S.I. Sequence of Helicobacter pylori-associated chronic gastritis in post-eradication period. Experimental and Clinical Pharmacology. 2007; 5:116–123. (In Russ.)].
  69. Кононов А.В., Мозговой С.И., Ливзан М.А. и др. Морфология поверхностного и атрофического хронического гастрита при эрадикации Helicobacter pylori. Архив патологии. 2005;3:17–21. [Kononov A.V., Mozgovoy S.I., Livzan M.A. et al. Morphology of superficial and atrophic chronic gastritis during Helicobacter pylori eradication. Pathology Archive. 2005; 3:17-21.(In Russ.)].
  70. Kyzekova J., Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology. 1999;46(27):2048–56.
  71. Abdul Rasheed Z., Gautam S., Ukabam S., Nayal S. Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. Digestion. 1999;60(3):286–97. DOI: 10.1159/000007673
  72. Genta R.M., Lew G.M., Graham D.Y. Changes in gastric mucosa following eradication of Helicobacter pylori. Mod Pathol. 1993;6(3):281–9.
  73. Rugge, M., Sugano, K., Sacchi, D., et al. Gastritis: An Update in 2020. Curr Treat Options Gastro. 2020;18:488– 503. DOI: 10.1007/s11938-020-00298-8
  74. Wang J., Xu L., Shi R., Huang X., Li S.W.H., Huang Z., et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011;83(4):253–60. DOI: 10.1159/000280318
  75. Rokkas T., Pistolias D., Sechopoulos P., Robotis I., Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12:32–8. DOI: 10.1111/j.1523-5378.2007.00563.x
  76. Kong Y.J., Yi H.G., Dai J.C., Wei M.-X. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903–11. DOI: 10.3748/wjg. v20.i19.5903
  77. McColl K., Murray L., El-Omar E., Dickson A., El-Nujumi A., Wirz A., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339(26):1869–74. DOI: 10.1056/NEJM199812243392601
  78. Madisch A., Miehlke S., Neuber F., Morgner A., Kuhlisch E., Rappel S., et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy — a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther. 2006; 23(4):473–9. DOI: 10.1111/j.1365-2036.2006.02778.x
  79. Lee V.W., Chau T.S., Chan A.K., Lee K.K., Waye M.M., Ling T.K., et al. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. J Clin Pharm Ther. 2010;35(3):343–50. DOI: 10.1111/j.1365-2710.2009.01088.x
  80. Liang X., Xu X., Zheng Q., Zhang W., Sun Q., Liu W., et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinoloneresistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802–7. DOI: 10.1016/j.cgh.2013.01.008
  81. Soh J.S., Kang H.S., Yang Y.J., Hong J.T., Shin S.P., Suk K.T., et al. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes. 2020;11(5):1314– 23. DOI: 10.1080/19490976.2020.1754118
  82. Chang Y.L., Tung Y.C., Tu Y.K., Yeh H.Z., Yang J.C., Hsu P.I., et al. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020;7(1):e000472. DOI: 10.1136/bmjgast-2020-000472
  83. Gisbert J.P., Castro-Fernández M., Bermejo F., PérezAisa A., Ducons J., Fernández-Bermejo M., et al. Thirdline rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006;101(2):243– 7. DOI: 10.1111/j.1572-0241.2006.00457.x
  84. Marzio L., Coraggio D., Capodicasa S., Grossi L., Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter. 2006;11(4):237–42. DOI: 10.1111/j.1523- 5378.2006.00407.x
  85. Yuan Y., Ford A.C., Khan K.J., Gisbert J.P., Forman D., Leontiadis G.I., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337. DOI: 10.1002/14651858. CD008337.pub2
  86. Gisbert J.P., McNicholl A.G. Optimization strategies aimed to increase the efficacy of H.pylori eradication therapies. Helicobacter. 2017;22(4). DOI: 10.1111/hel.12392
  87. Villoria A., Garcia P., Calvet X., Gisbert J.P., Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28(7):868–77. DOI: 10.1111/j.1365-2036.2008.03807.x
  88. Vallve M., Vergara M., Gisbert J.P., Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002;16(6):1149–56. DOI: 10.1046/j.1365-2036.2002.01270.x
  89. McNicholl A.G., Linares P. M., Nyssen O.P., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414– 25. DOI: 10.1111/j.1365-2036.2012.05211.x
  90. Ko S.W., Kim Y.-J., Chung W.C., Lee S.J. Bismuth supplements as the firstline regimen for Helicobacter pylori eradication therapy: Systemic review and metaanalysis. Helicobacter. 2019; 24(2):e12565. DOI: 10.1111/hel.12565
  91. Dore M.P., Lu H., Graham D.Y. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870–8. DOI: 10.1136/ gutjnl-2015-311019
  92. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014; 9(11):e111030. DOI: 10.1371/journal.pone.0111030
  93. McFarland L.V., Huang Y., Wang L., Malferthei ner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterology Journal. 2016;4(4):546–61. DOI: 10.1177/2050640615617358
  94. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707–16. DOI: 10.3892/etm.2015.2174 94. Zhang M.-M., Qian W., Qin Y.-Y., He J., Zhou Y.-H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345–57. DOI: 10.3748/wjg.v21.i14.4345
  95. Nishizawa T., Nishizawa Y., Yahagi N., Kanai T., Takahashi M., Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(4):20–4. DOI: 10.1111/jgh.12769
  96. Du Y., Bai Y., Xie P., Fang J., Wang X., Hou X., et al. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol. 2014;14:21. DOI: 10.1186/1471- 230X-14-21
  97. Hawkey C.J., Wilson I., Naesdal J., Långström G., Swannell A.J., Yeomans N.D. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51(3):344–50. DOI: 10.1136/gut.51.3.344
  98. Ng F.H., Wong S.Y., Lam K.F., Chu W.M., Chan P., Ling Y.H., et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82–88. DOI: 10.1053/j.gastro.2009.09.063
  99. Wilson I., Långström G., Wahlqvist P., Walan A., Wiklund I., Naesdal J. Management of gastroduodenal ulcers and gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug therapy: A summary of four comparative trials with omeprazole, ranitidine, misoprostol, and placebo. Current therapeutic research. 2001;62(12):835–50.
  100. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. Мартынов А.И., Яхно Н.Н., Арутюнов Г.П. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1–29. [Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P., et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1–29 (In Russ.)]. DOI: 10.14412/1995-4484-2018-1-29
  101. Du Y., Li Z., Zhan X., Chen J., Gao J., Gong Y., et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. DigDisSci. 2008;53(11):2886–95. DOI: 10.1007/s10620-007-0180-z
  102. Kim G.H., Lee H.L., Joo M.K., Park H.J., Jung S.W., Lee O.J., et al. Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double- Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study. Gut Liver. 2021. DOI: 10.5009/gnl20338
  103. Kumar S., Dewan B., Shah D. A Comparative Evaluation of Lafutidine and Rabeprazole in the Treatment of Gastritis and Peptic Ulcer: A Double-blind, Randomized Study in Indian Patients. Journal of Advances in Medicine and Medical Research. 2013;3(4):1187–98. DOI: 10.9734/ BJMMR/2013/3173
  104. Кононов А.В., Мозговой С.И., Рыбкина Л.Б., Бунова С.С., Шиманская А.Г. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori и пролонгированном приеме препарата. Рос журн гастроэнтерол гепатол колопроктол. 2006;16(6):21–8. [Kononov A.V., Mozgovoy S.I., Rybkina L.B., Bunova S.S., Shimanskaya A.G. Assessment of bismuth tripotassium dicitrate cytoprotective effect on stomach mucosa at H. pylori eradication and prolonged drug administration. Rus J Gastroenterol Hepatol Coloproctol. 2006;16(6):21–8 (In Russ.)].
  105. Лапина Т.Л. Возможности лекарственного воздействия на цитопротективные свойства гастродуоденальной слизистой оболочки. Рос жур гастроэнтерол гепатол колопроктол. 2006;16(5):2–7. [Lapina T.L. Pharmaceutical options of modulation gastroduodenal mucosa cytoprotection. Rus J Gastroenterol Hepatol Coloproctol. 2006;16(5):2–7 (In Russ.)].
  106. Han X., Jiang K., Wang B., Zhou L., Chen X., Li S. Effect of rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin Drug Investig. 2015;35(10):665–73. DOI: 10.1007/s40261-015- 0329-z
  107. Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T., Matsumoto H., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146 — 86514. DOI: 10.1155/2015/865146
  108. Simadibrata, M., Syam, A., Rani, A., Wanandi, S., Fauzi, A., Abdullah, M. Anti free radical & anti inflammatory effect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013;3:72–7. DOI: 10.4236/ ojgas.2013.31011
  109. Seo G.H., Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221–8. DOI: 10.1159/000495288
  110. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261–70. DOI: 10.1586/ egh.10.25
  111. Haruma K., Ito M. Review article: clinical significance of mucosal- protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment PharmacolTher. 2003;18(1):153-9. DOI: 10.1046/j.1365-2036.18.s1.17.x
  112. Pinto-Sanchez M.I., Yuan Y., Hassan A., Bercik P., Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. DOI: 10.1002/14651858.CD011194.pub3
  113. Moayyedi P., Delaney B.C., Vakil N., Forman D., Talley N.J. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127(5):1329–37. DOI: 10.1053/j. gastro.2004.08.026
  114. Oh J.H., Kwon J.G., Jung H.K., Tae C.H., Song K.H., Kang S.J., et al. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J NeurogastroenterolMotil. 2020;26(1):29–50. DOI: 10.5056/jnm19209
  115. Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011
  116. Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. DOI: 10.1186/s12876-0170639-0
  117. Huang X., Lv B., Zhang S., Fan Y.H., Meng L.N. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18(48):7371–7. DOI: 10.3748/wjg.v18.i48.7371
  118. Veldhuyzen van Zanten S.J., Jones M.J., Verlinden M., Talley N.J. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96(3):689–96. DOI: 10.1111/j.1572- 0241.2001.03521.x
  119. Zhong Y.Q., Zhu J., Guo J.N., Yan R., Li H.J., Lin Y.H., et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome. ZhonghuaNeiKe Za Zhi. 2007;46(11):899–902
  120. Kountouras J., Gavalas E., Papaefthymiou A., Tsechelidis I., Polyzos S.A., Bor S., et al. Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. Medicina (Kaunas). 2020;56(7):339. DOI: 10.3390/medicina56070339
  121. Кардашева С.С., Картавенко И.М., Максимова Н.Б., Юрьева Е.Ю., Попова И.Р., Павлов Ч.С., Ивашкин В.Т. Эффективность тримебутина малеата в лечении пациентов с функциональной диспепсией: результаты наблюдательного исследования «TREND». Рос журн гастроэнтерол гепатол колопроктол. 2018;28(5):67–76. [Kardasheva S.S., Kartavenko I.M., Maksimova N.B., Yurieva E.Yu., Popova I.R., Pavlov Ch.S., Ivashkin V.T. Efficacy of Trimebutine Maleate (Trimedat®) in the Treatment of Patients with Functional Dyspepsia: Results of the “TREND” Observational Study. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(5):67–76 (In Russ.)]. DOI: 10.22416/1382-4376-2018-28-5-67-76
  122. Андреев Д.Н., Маев И.В. Эффективность тримебутина в рамках лечения функциональных заболеваний желудочно-кишечного тракта и желчных путей: наблюдательное многоцентровое исследование. Терапевтический архив. 2021;93(8):897–903. [Andreev D.N., Maev I.V. Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study. Terapevticheskii arkhiv. 2021;93(8):897–903 (In Russ.)]. DOI: 10.26442/00403660.2021.08.200919
  123. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355–61. DOI: 10.1046/j.1365-2036.2001.00937.x
  124. Holtmann G., Talley N. J., Liebregts T., Adam B., Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354(8):832–40. DOI: 10.1056/NEJMoa052639
  125. Ивашкин В.Т., Шептулин А.А., Трухманов А.С. Эффективность применения ганатона (итоприда гидрохлорида) в лечении больных функциональной диспепсией. Фарматека. 2009;13:50–4.[ Ivashkin V.T., Sheptulin A.A., Trukhmanov A.S. Efficacy of ganaton (itopride hydrochloride) in treatment for functional dyspepsia. Farmateka. 2009; 13:50-4. (In Russ.)].
  126. Sawant P., Das H.S., Desai N., Kalokhe S., Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India. 2004;52:626–8.
  127. Лазебник Л.Б., Алексеенко С.А., Лялюкова Е.А. и др. Рекомендации по ведению первичных пациентов с симптомами диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018; 5:4–18.[ Lazebnik L.B., Alekseenko S.A., Lyalyukova E.A. et al. Guidelines on primary patient management in dyspepsia. Experimental and Clinical Gastroenterology. 2018;(5):4-18. (In Russ.)].
  128. Jaafar M.H., Safi S.Z., Tan M.P., Rampal S., Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250–60. DOI: 10.1007/s10620-0174871-9
  129. Zhao G., Xue M., Hu Y., Lai S., Chen S., Wang L. How commonly is the diagnosis of gastric low grade dysplasia upgraded following endoscopic resection? A meta-analysis. PLoSOne 2015;10(7):e0132699. DOI: 10.1371/journal. pone.0132699
  130. Sung J.K. Diagnosis and management of gastric dysplasia. Korean J InternMed. 2016;31(2):201–9. DOI: 10.3904/ kjim.2016.021
  131. Correa P. Clinical implications of recent developments in gastric can- cer pathology and epidemiology. Semin Oncol. 1985;12:2–10.
  132. Lauwers G., Carneiro F., Graham D., et al. Gastric carcinoma. In: Theise N, ed. WHO Classification of tumours of the digestive system. Lyon: IARC Press. 2010;48–58.
  133. Лейзерман В.Г., Бугрова О.В., Красикова С.И. Восстановительная медицина. М.: Феникс, 2008. [Leyzerman V.G., Bugrova O.V., Krasikova S.I. Restorative medicine. Feniks. 2008 (In russ.)].
  134. Lee Y.C., Chiang T.H., Chou C.K., Tu Y.-K., Liao W.-C., Wu M.-S., et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–24.e5. DOI: 10.1053/j.gastro.2016.01.028
  135. Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020; 69(12):2113-2121. DOI: 10.1136/gutjnl-2020-320839
  136. Chiang T.H., Chang W.J., Chen S.L., Yen A.M., Fann J.C., Chiu S.Y., et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243–50. DOI: 10.1136/gutjnl-2020-322200.
  137. Ma J.L., Zhang L., Brown L.M., Shen L., Pan K.-F., Liu W.-D. et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488– 92. DOI: 10.1093/jnci/djs003
  138. Wong B.C.-Y, Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187–94. DOI: 10.1001/jama.291.2.187
  139. Choi I.J., Kook M.C., Kim Y.I., Cho S.-J., Lee J.Y., Kim C.G., et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085–95. DOI: 10.1056/NEJMoa1708423
  140. Bang C.S., Baik G.H., Shin I.S., Kim J.B., Suk K.T., Yoon J.H., et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci. 2015;30(6):749–56.
  141. Jung D.H., Kim J.H., Chung H.S., Park J.C., Shin S.K., Lee S.K., et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoSOne. 2015;10(4):e0124725. DOI: 10.1371/journal.pone.0124725
  142. Ивашкин В.Т., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Маев И.В., Драпкина О.М. и др. Практические шаги по профилактике рака желудка в Российской Федерации: алгоритм ведения пациентов с хроническим геликобактерным гастритом (Материалы и резолюция совета экспертов 9 декабря 2013 г.). Рос журн гастроэнтерол гепатол колопроктол. 2014;24(2):102–4. [Ivashkin V.T., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Maev I.V., Drapkina O.M., et al. Practical steps on stomach cancer prevention in the Russian Federation: H. pyloriassociated gastritis management algorithm (Advisory board position statement, December, 9, 2013). Rus J Gastroenterol Hepatol Coloproctol. 2014;24(2):102–4 (In Russ.)].
  143. Song H., Ekheden I.G., Zheng Z., et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015; 351: h3867. DOI: 10.1136/bmj. h4134
  144. Rugge M., Meggio A., Pravadelli C., Barbareschi M., Fassan M., Gentilini M., et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019;68(1):11–7. DOI: 10.1136/gutjnl-2017-314600
  145. Cho S.J., Choi I.J, Kook M.C., Nam B.-H., Kim C.G., Lee J.Y., et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013;38(10):1292–302. DOI: 10.1111/apt.12515
  146. Kodama M., Murakami K., Okimoto T., Abe H., Sato R., Ogawa R., et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol. 2013;48(11):1249– 56. DOI: 10.3109/00365521.2013.838994
  147. Mera R.M., Bravo L.E., Camargo M.C., Bravo J.C., Delgado A.G., Romero-Gallo J., et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7):1239–46. DOI: 10.1136/ gutjnl-2016-311685
  148. Gonzalez C.A., Sanz-Anquela J.M., Companioni O., Bonet C., Berdasco M., López C., et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol. 2016;31(5):953–8. DOI: 10.1111/jgh.13249.
  149. Gonzalez C.A., Sanz-Anquela J.M., Gisbert J.P., Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer. 2013;133(5):1023–32. DOI: 10.1002/ijc.28003
  150. Conchillo J.M., Houben G., de Bruine A., Stockbrügger R. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev. 2001; 10(4):307 –312. doi: 10.1097/00008469-200108000-00003.
  151. Rokkas T., Sechopoulos P., Pistiolas D., Georgios Margantinis, Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2010; 22(9):1128–33. DOI: 10.1097/MEG.0b013e3283398d37
  152. Marcos-Pinto R., Dinis-Ribeiro M., Carneiro F., Wen X., Lopes C., Figueiredo C., et al. First-degree relatives of early-onset gastric cancer patients show a high risk for gas tric cancer: phenotype and genotype profile. Virchows Arch. 2013;463(3):391–9. DOI: 10.1007/s00428013-1458-5
  153. Vannella L., Lahner E., Osborn J., Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013;37(4):375–82. DOI: 10.1111/apt.12177
  154. Sjoblom S.M., Sipponen P., Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut. 1993;34(1):28–32. DOI: 10.1136/gut.34.1.28
  155. Brinton L.A., Gridley G., Hrubec Z., Hoover R., Fraumeni J.F. Cancer risk following pernicious anaemia. Br J Cancer. 1989;59(5):810 –3. DOI: 10.1038/bjc.1989.169
  156. Kim H.H., Uedo N. What Have We Accomplished in Endoscopic Image Analysis for Atrophic Gastritis? Korean J Helicobacter Upper Gastrointest Research. 2013;13(1):6– 19. DOI: 10.7704/kjhugr.2013.13.1.6
  157. Toyoshima O., Nishizawa T., Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J Gastroenterol 2020;26(5):466–77. DOI: 10.3748/wjg.v26.i5.466

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Литература / References
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*